Treatment with mirvetuximab soravtansine, an antibody-drug conjugate (ADC) targeting folate receptor-alpha (FRα), led to significantly better survival outcomes in women with platinum-resistant ovarian cancer (PROC) compared with the investigator’s choice of chemotherapy, according to the MIRASOL trial presented at ASCO 2023.
The addition of pembrolizumab immunotherapy to chemotherapy, either with or without bevacizumab, continues to confer survival benefit in patients with persistent, recurrent, or metastatic cervical cancer, regardless of their programmed death-ligand 1 (PD-L1) combined positive score (CPS), according to the updated results of the KEYNOTE-826 trial presented at ASCO 2023.
The oral drug vorasidenib delays disease progression compared with placebo in patients with residual or recurrent grade 2 gliomas harbouring an isocitrate dehydrogenase 1 or 2 (IDH1 or IDH2) mutation in the phase III INDIGO trial.
A novel electronic health record (EHR) clinical decision support tool, otherwise called the AH-HA* tool, was effective in promoting cardiovascular health (CVH) discussions among cancer survivors during routine follow-up. This was the primary result of a clinic-randomized, hybrid effectiveness-implementation trial presented at ASCO 2023.
Treatment with sacituzumab govitecan (SG) demonstrates clinically meaningful overall survival (OS) over single-agent chemotherapy in patients with pretreated, endocrine-resistant, hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC), as confirmed by the final OS analysis from the TROPiCS-02 study, presented at ASCO 2023.
Treatment with nivolumab (N) plus doxorubicin, vinblastine, and dacarbazine (AVD) leads to improved progression-free survival (PFS) relative to brentuximab vedotin (BV) plus AVD in patients with advanced stage classic Hodgkin lymphoma (HL), according to the results of the SWOG S1826 study, which was presented at the recent ASCO 2023.
The oral selective pan-FGFR tyrosine kinase inhibitor (TKI) erdafitinib demonstrated a survival advantage over chemotherapy, extending multiple efficacy endpoints in individuals with advanced or metastatic urothelial carcinoma (mUC) with FGFR alterations (FGFRalt) after previous anti-PD-(L)1 treatment, findings from the confirmatory phase III THOR trial have shown.
In the treatment of patients with colon cancer, neoadjuvant chemotherapy does not appear to yield better survival benefit than standard upfront surgery, according to the results of the phase III NeoCol trial presented at ASCO 2023.
In the second interim efficacy analysis of the phase III NATALEE trial, a combination regimen comprising the CDK4/6 inhibitor ribociclib and endocrine therapy (ET) demonstrated favourable signals for the adjuvant treatment of stage II/III hormone receptor-positive, HER2-negative (HR+, HER2–) early breast cancer.
For patients with advanced nonsmall cell lung cancer (NSCLC) who remain progression-free on immune checkpoint inhibitor (ICI)-based therapy at 2 years, continuing treatment does not appear to confer any survival advantage as opposed to stopping, according to a retrospective study presented at ASCO 2023.